Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity

Rejuva

June 23, 2024 by

May 20, 2024 by

December 28, 2023 by

October 28, 2023 by

June 29, 2023 by

May 29, 2023 by

May 28, 2023 by

December 28, 2022 by

November 29, 2017 by

Our Focus
- Obesity
- Type 2 Diabetes
Our Platforms
- Revita
- Rejuva
Our Science
- Clinical Studies
- Presentations & Publications
Our Company
- Culture
- Our Team
- Careers
Our News
- Media Kit
Investors